Şunu aradınız:: lopid (İngilizce - Estonca)

lopid
lopid

lopid tc
lopid tc

lopid should be taken orally.
lopiidi tuleb võtta suu kaudu.

lopid via valbondione 113 i – 00188 roma
via valbondione 113 i – 00188 rooma

lopid should not be used when breast feeding.
lopid’ i ei tohi kasutada imetamise ajal.

lopid and associated names (see annex i)
lopid ja sellega seotud nimetused (vt i lisa)

it was proposed to rationalise the authorised strengths of lopid.
tehti ka ettepanek määrata lopiidi lubatud tugevused.

due to the lack of data the use of lopid in children is not recommended.
andmete puudumise tõttu ei soovitata lopid’ i lastele.

pregnancy there are no adequate data on use of lopid in pregnant women.
rasedus lopid’ i kasutamise kohta rasedatel naistel ei ole piisavalt andmeid.

lopid parke davis lambert court chestnut avenue eastleigh hampshire so53 3zq united kingdom
parke davis lambert court chestnut avenue eastleigh hampshire so53 3zq Ühendkuningriik

overall summary of the scientific evaluation of lopid and associated names (see annex i)
lopiidi ja sellega seotud nimede (vt lisa i) teadusliku hinnangu ÜldkokkuvÕte

in addition, recently reported interactions with other medicinal products have been added to the spc for lopid.
4. 5.

lopid should not be used in patients with severely impaired renal function (see section 4.3).
tugeva neerukahjustusega patsiendid ei tohiks lopiidi kasutada (vt lõik 4. 3).

the mah was requested to propose and scientifically justify a common eu wide approach as there were divergences between national approvals regarding the use of lopid in:
müügiloa hoidjal (mah) paluti esitada ja teaduslikult põhjendada eli ühtne kontseptsioon, kuna eri riikides esines lahknevusi lopiidi kasutamise lubamisel järgmistel juhtudel:

the cpmp has recommended the amendment of the marketing authorisations for which the summary of product characteristics is set out in annex iii of the opinion for lopid and associated names (see annex i).
soovitab patendiravimite komitee (cpmp) sisse viia müügiloa hoidjate esitatud muudatuse, mis on ära märgitud ravimi omaduste kokkuvõtte lisas iii – arvamus lopiidi ja sellega seotud nimede kohta (vt lisa i).

lopid is indicated as an adjunct to diet and other non-pharmacological treatment (e. g. exercise, weight reduction) for the following:
lopid on näidustatud täiendavalt dieedile ja muule mittefarmakoloogilisele ravile (nt füüsiline aktiivsus, kehakaalu vähendamine) järgmistel juhtudel:

interaction with other medicinal products and other forms of interaction after an assessment of the documentation provided by the mah and an evaluation of the current eu- wide clinical practices relating to the use of lopid, the most suitable harmonised section 4.5 interaction with other medicinal products and other forms of interaction (see annex iii).
lopiidi omaduste kokkuvõttesse lisati ka hiljuti saadud andmed koostoime kohta muude ravimpreparaatidega.